Skip to content
value.today

Immutrix Therapeutics, Inc.

Total raised
$13 M
3 rounds on record
Latest round
$5 M
Nov 2017
First round on record
Jun 2014
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Immutrix Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2017$5 MNo. 3$2 to $10 million

Immutrix Therapeutics, Inc.: Raise no. 3, Nov 2017

Investors in this round

26 investors had bought by the notice of Oct 12, 2018: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $16 M offered; $11 M still to sell
Smallest investment taken
$50,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carol A. Rae · Executive Officer, Director · President & CEO
  • Leroy A. Ketel · Executive Officer, Director · CFO and Secretary
  • Brent A. Phillips · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Carol A Rae, President. Source: SEC Form D, newest notice filed Oct 12, 2018. Read the notice at the SEC.

equitySEC
Oct 2015$4 MNo. 2$2 to $10 million

Immutrix Therapeutics, Inc.: Raise no. 2, Oct 2015

Investors in this round

1 investor had bought by the notice of Oct 20, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $7 M offered; $3 M still to sell
Smallest investment taken
$2,600,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carol Rae · Executive Officer, Director · CEO, President
  • Leroy Ketel · Executive Officer, Director · CFO, Secretary
  • Brent Phillips · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Leroy Ketel, CFO, Secretary & Director. Source: SEC Form D, newest notice filed Oct 20, 2015. Read the notice at the SEC.

equitySEC
Jun 2014$4 MNo. 1$2 to $10 million

Immutrix Therapeutics, Inc.: Raise no. 1, Jun 2014

Investors in this round

34 investors had bought by the notice of Jul 22, 2016: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
$1,500
What was sold
equity, other: Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$506,377 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carol Rae · Executive Officer, Director · CEO, President
  • Leroy Ketel · Executive Officer, Director · CFO, Secretary
  • Brent Phillips · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Carol Rae, President. Source: SEC Form D and 1 amendment, newest notice filed Jul 22, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Immutrix Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2018).

    SEC Form D · Oct 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2018

That is all the official record says: Immutrix Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Immutrix Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 34 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Immutrix Therapeutics, Inc.
NameRoleNamed in
Carol A. RaePresident & CEOOct 2018
Leroy A. KetelCFO and SecretaryOct 2018
Carol RaeCEO, PresidentJul 2016
Leroy KetelCFO, SecretaryJul 2016
Brent A. PhillipsDirectorOct 2018
Carol A. RaePresident & CEOOct 2018
Leroy A. KetelCFO and SecretaryOct 2018
Brent PhillipsDirectorJul 2016
Carol RaeCEO, PresidentJul 2016
Leroy KetelCFO, SecretaryJul 2016